Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | USP9X | Q93008 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14874901 | 0.80 | MAPT (0.35) | LSSKCNH2HRH3LTA4H | |
| SCHEMBL14573122 | 0.80 | ALDH1A1 (0.49) | LSSKCNH2HRH3SMN1; SMN2MMP12 | |
| SCHEMBL14874900 | 0.77 | RAB9A (0.49) | KCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL132013 | 0.77 | KCNH2 (0.49) | LSSKCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL14875009 | 0.77 | G6PD (0.49) | LSSKCNH2HRH3SMN1; SMN2MMP12 | |
| SCHEMBL4576309 | 0.75 | LSS (0.42) | LSSKCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL2435102 | 0.75 | LSS (0.45) | LSSKCNH2HRH3LTA4H | |
| SCHEMBL14947206 | 0.74 | LSS (0.40) | LSSKCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL16771905 | 0.74 | LSS (0.40) | LSSKCNH2HRH3LTA4HSMN1; SMN2 | |
| SCHEMBL5611161 | 0.72 | NOTUM (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802593-B1 | POLYMER-FILLER COUPLING ADDITIVES | BRIDGESTONE CORP (JP) | 2013-04-24 | — | — | EP | claimed |
| US-9045432-B2 | Nitrile oxide, nitrone, and nitrile imine compounds | ARKEMA FRANCE (FR) | 2015-06-02 | — | — | US | disclosed |
| US-20130197237-A1 | MOLECULES HAVING COMBINABLE GROUPS | ARKEMA FRANCE (FR) | 2013-08-01 | — | — | US | disclosed |
| EP-1802593-B1 | POLYMER-FILLER COUPLING ADDITIVES | BRIDGESTONE CORP (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-7186845-B2 | Polymer-filler coupling additives | BRIDGESTONE CORPORATION (JP) | 2007-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197237-A1 | MOLECULES HAVING COMBINABLE GROUPS | NCAPH, NCL, PARG | LSS 2568/4885KCNH2 3624/4885HRH3 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.